Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KEY's NITRO-DUR II RECEIVES ADDED BOOST FROM SCHERING SALES FORCE

Executive Summary

KEY's NITRO-DUR II RECEIVES ADDED BOOST FROM SCHERING SALES FORCE, which began detailing Key's new nitroglycerin patch even before the merger of the two companies was finalized on June 26. Commenting to analysts June 17 on the Schering/Key advance, Schering-Plough Chairman Robert Luciano noted: "With a larger total sales force, we can afford to specialize to a greater extent, and in selected instances put more force behind the introduction of new products." Luciano added: "A good example of this opportunity being put into practice is the fact that in mid-June, Schering's field force began to conpromote Key's Nitro-Dur II." The combination of the two sales forces puts approximately 1,100 detail people behind Nitro-Dur II sales in the U.S. The Key acquisition provides Schering with an additional 280 cardiovascular and allergy sales people on top of Schering's 800-plus U.S. detail force. Nitro-Dur II generated sales of $46 mil. in 1985 for Key. In addition to giving Schering a specialized cardiovascular and allergy field force, the Key merger also expands Schering's marketing capabilities enough to allow greater specialization within the Schering sales arm. Luciano noted that the company's launch of Intron-A is being supported with a newly formed anticancer/antiviral detail force Luciano also indicated plans to expand Key's sales force while giving Schering management tighter rein. "We will be moving Key's marketing organization from Florida up to New Jersey during the course of the summer, but it is our intention to keep the sales forces separate," Luciano remarked. "We expect to enlarge the Key field force and to utilize our two sales forces to concentrate on particular product areas, cardiovascular, allergy/asthma and cough/cold. When we want a major promotion . . . we'll have both sales forces detail the same product."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel